Vericiguat Modulates Osteoclast Differentiation and Bone Resorption via a Balance between VASP and NF-κB Pathways

Figure 6

VASP was essential to osteoclast differentiation, and the expression of VASP could be promoted by Vericiguat. (a) VEGT augmented the expression of VASP in a dosage-dependent manner (). (b, c) RANKL enhanced the expression of VASP in a dosage-dependent manner and quantitative results (). indicated a comparison with the control group without RANKL. (d) Immunofluorescence position of VASP in BMMs with or without RANKL. (e) The mRNA expression of VASP in BMMs after treatment with siRNA (); indicated a comparison with the control group (si-NC). (f, g) The protein expression of VASP in BMMs after treatment with siRNA and quantitative results (). indicated a comparison with the control group (si-NC). (h–l) The mRNA expression of OC-related genes in BMMs after treatment with siRNA (). indicated a comparison with the control group: , , , and . # indicated a comparison between the group with si-VASP and the group with si-NC: ^#, ^##, ^###, and ^####. (m) The protein expression of osteoclast-related genes in BMMs after treatment with siRNA and quantitative results (). (n, o) The expression of NF-κB protein in BMMs with or without siRNA-VASP treated with Vericiguat only (). (p) The mRNA expression of osteoclast-related genes (NFATc1, TRAP, and β3-Integrin) in siRNA-VASP-induced BMMs compared with siRNA-NC-induced BMMs (); indicated a comparison with the control group (Vericiguat, 0 nM) in the siRNA-NC group and si-VASP group, respectively: , , , and . # indicated a comparison between the siNC-induced group and si-VASP-induced group at the same concentration of Vericiguat: ^#, ^##, ^###, and ^####. .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)

(p)